Business model

Business model

PharmaLundensis AB develops PHAL-501 as a new, effective and mild drug to bind and excrete the heavy metals mercury, lead and cadmium from the body. This is expected to provide a major improvement in several diseases, such as COPD and chronic bronchitis, and also depression.

Phal-501 will be tested and optimized in clinical studies and then registered as a drug in the desired markets. Sales will then be made in-house or out-licensed in selected markets.

Another option, which could run in parallel with drug development, is to develop Phal-501 into a medical device that, once registered, may be sold over-the-counter in grocery stores in all EU countries. A medical device is often easier, quicker and cheaper to bring to market than a drug.

In the development of Phal-501 as a drug, it will initially be given to seriously ill patients with, for example, severe COPD where there is no other effective treatment. Given that Phal-501 is only expected to have very few, if any, side effects, there is every reason to believe that the treatment will receive “Fast Track” approval from the regulatory authorities, allowing it to reach the market quickly.